Research programme: ketamine deuterated - Teva Pharmaceutical Industries

Drug Profile

Research programme: ketamine deuterated - Teva Pharmaceutical Industries

Alternative Names: Deuterium-containing ketamine - Teva Pharmaceutical Industries

Latest Information Update: 28 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Auspex Pharmaceuticals
  • Developer Teva Pharmaceutical Industries
  • Class Analgesics; Inorganic deuterium compounds; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for preclinical development in Pain in USA
  • 05 May 2015 Auspex Pharmaceuticals has been acquired by Teva Pharmaceutical Industries
  • 18 Mar 2014 Preclinical trials in Pain in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top